Medicare Enrolled

Dr. Edmund Tsui, MD

Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician · Los Angeles, CA
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Mixed engagement
200 STEIN PLAZA #1-340, Los Angeles, CA 90095
3108255000
In practice since 2014 (11 years)
NPI: 1255743712 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Tsui from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Tsui? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Tsui

Dr. Edmund Tsui is an uveitis and ocular inflammatory disease physician in Los Angeles, CA, with 11 years of NPI registration. Based on federal Medicare data, Dr. Tsui performed 602 Medicare services across 280 unique beneficiaries.

Between the years covered by Open Payments, Dr. Tsui received a total of $11,373 from 13 pharmaceutical and/or device companies across 34 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in uveitis and ocular inflammatory disease (ophthalmology) physician. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Tsui is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 11 years in practice ▲ 602 Medicare services $11,373 industry payments

Medicare Practice Summary

Medicare Utilization ↗
602
Medicare services
Bottom 33% in CA for uveitis and ocular inflammatory disease (ophthalmology) physician
Lower Medicare volume may reflect subspecialty focus, hospital-based work, or a higher share of non-Medicare patients.
280
Unique beneficiaries
$88
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~55 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
 373 $107 $858
Retinal imaging (OCT scan)
This procedure involves imaging the retina to visualize its structure. It is used to examine the back of the eye.
 130 $33 $363
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
 65 $73 $508
Comprehensive eye exam, established patient
A comprehensive examination of the visual system performed for a patient who has previously been seen by the provider.
 23 $97 $835
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
 11 $143 $1,085
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$11,373
Total received (2018-2024)
Avg $2,275/year across 5 years
Bottom 33% in CA for uveitis and ocular inflammatory disease (ophthalmology) physician
13
Companies
34
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$4,075 (35.8%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,702 (32.6%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$3,596 (31.6%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$2,571
2023
$2,832
2022
$2,500
2021
$1,845
2018
$1,625

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
ANI Pharmaceuticals, Inc.
$1,575
Bausch & Lomb Americas Inc.
$682
ABBVIE INC.
$172
Sight Sciences, Inc.
$142
Top 3 companies account for 94.5% of 2024 payments
All-time payments by company (2018-2024) ›
EyePoint Pharmaceuticals US, Inc.
$3,596
KOWA COMPANY, LTD.
$2,500
ANI Pharmaceuticals, Inc.
$1,693
Bausch & Lomb Americas Inc.
$1,072
Regeneron Pharmaceuticals, Inc.
$1,055
Alcon Laboratories Inc
$328
Sight Sciences, Inc.
$288
AbbVie Inc.
$212
ABBVIE INC.
$172
Genentech USA, Inc.
$139
Bausch & Lomb, a division of Bausch Health US, LLC
$115
Genentech, Inc.
$103
Mallinckrodt Hospital Products Inc.
$100
Top 3 companies account for 68.5% of all-time payments
Associated products mentioned in payments ›
ACTHAR · AcrySof · Centurion · DOCTORS ALLERGY FORMULA · Lucentis · MIEBO · Non-Covered Product · OMNI SURGICAL SYSTEM · OZURDEX · PURIFIED CORTROPHIN GEL · XIPERE · YUTIQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (36%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in uveitis and ocular inflammatory disease (ophthalmology) physician and does not inherently indicate bias, but patients may wish to be aware.

Looking for an uveitis and ocular inflammatory disease physician in Los Angeles?
Compare uveitis and ocular inflammatory disease physicians in the Los Angeles area by procedure volume, costs, and industry payment transparency.
Browse uveitis and ocular inflammatory disease physicians nearby

Geographic Context

Uveitis and ocular inflammatory disease physicians within 10 mi
2
Per 100K population
0.0
County median income
$87,760
Nearest hospital
RONALD REAGAN UCLA MEDICAL CENTER
0.0 mi

Data Sources

Provider Registry ✓ NPPES Weekly updates
Medicare Enrollment ✓ PECOS Monthly updates
Practice Data ✓ Medicare Util. Annual (CY lag)
Industry Payments ✓ Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Tsui is a clinical cardiology specialist, with moderate Medicare volume, with mixed engagement industry engagement.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Tsui experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Tsui performed 373 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Tsui receive payments from pharmaceutical companies?
Yes. Dr. Tsui received a total of $11,373 from 13 companies across 34 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Tsui's costs compare to other uveitis and ocular inflammatory disease physicians in Los Angeles?
Dr. Tsui's average Medicare payment per service is $88. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Tsui) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →

Explore related providers

Same specialty & city
Uveitis And Ocular Inflammatory Disease Physicians in Los Angeles
Browse uveitis and ocular inflammatory disease physicians in Los Angeles ranked by procedure volume and transparency data.
Highest volume
Top Uveitis And Ocular Inflammatory Disease Physicians in CA
Uveitis and ocular inflammatory disease physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Uveitis And Ocular Inflammatory Disease Physicians in CA
Which CA uveitis and ocular inflammatory disease physicians receive the most from drug and device companies.
By company
EyePoint Pharmaceuticals US, Inc. Payments to Doctors
See all physicians who received payments from EyePoint Pharmaceuticals US, Inc.
By company
KOWA COMPANY, LTD. Payments to Doctors
See all physicians who received payments from KOWA COMPANY, LTD.
By company
ANI Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from ANI Pharmaceuticals, Inc.
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →